Sunesis Pharmaceuticals Company Profile (NASDAQ:SNSS)

About Sunesis Pharmaceuticals (NASDAQ:SNSS)

Sunesis Pharmaceuticals logoSunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company's other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:SNSS
  • CUSIP: 86732860
  • Web:
  • Market Cap: $43.5 million
  • Outstanding Shares: 23,513,000
Average Prices:
  • 50 Day Moving Avg: $2.13
  • 200 Day Moving Avg: $2.73
  • 52 Week Range: $1.84 - $4.45
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.33
  • P/E Growth: -0.01
Sales & Book Value:
  • Annual Revenue: $1.96 million
  • Price / Sales: 22.19
  • Book Value: ($0.27) per share
  • Price / Book: -6.85
  • EBITDA: ($34,640,000.00)
  • Net Margins: -1,472.94%
  • Return on Assets: -112.07%
  • Current Ratio: 3.36%
  • Quick Ratio: 3.36%
  • Average Volume: 150,042 shs.
  • Beta: 1.52
  • Short Ratio: 5.5

Frequently Asked Questions for Sunesis Pharmaceuticals (NASDAQ:SNSS)

What is Sunesis Pharmaceuticals' stock symbol?

Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."

How were Sunesis Pharmaceuticals' earnings last quarter?

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) released its quarterly earnings data on Thursday, July, 27th. The company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.76) by $0.35. During the same period in the prior year, the company posted ($0.12) earnings per share. View Sunesis Pharmaceuticals' Earnings History.

When will Sunesis Pharmaceuticals make its next earnings announcement?

Sunesis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Sunesis Pharmaceuticals.

Where is Sunesis Pharmaceuticals' stock going? Where will Sunesis Pharmaceuticals' stock price be in 2017?

2 brokers have issued 12 month target prices for Sunesis Pharmaceuticals' shares. Their predictions range from $3.00 to $3.00. On average, they expect Sunesis Pharmaceuticals' share price to reach $3.00 in the next year. View Analyst Ratings for Sunesis Pharmaceuticals.

What are analysts saying about Sunesis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Sunesis Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. " (10/4/2017)
  • 2. Cantor Fitzgerald analysts commented, "Interim data analysis from Phase Ib study of BTK inhibitor SNS-062 is expected in mid-2018, possibly at ASCO." (9/27/2017)

Who are some of Sunesis Pharmaceuticals' key competitors?

Who are Sunesis Pharmaceuticals' key executives?

Sunesis Pharmaceuticals' management team includes the folowing people:

  • Daniel N. Swisher Jr., President, Chief Executive Officer, Director
  • Adam R. Craig M.D., Ph.D., Executive Vice President - Development, Chief Medical Officer
  • James W. Young Ph.D., Non-Executive Independent Chairman of the Board
  • Stephen B. Ketchum Ph.D., Director
  • Geoffrey M. Parker, Director
  • Steve R Carchedi, Independent Director
  • Matthew K. Fust, Independent Director

How do I buy Sunesis Pharmaceuticals stock?

Shares of Sunesis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sunesis Pharmaceuticals' stock price today?

One share of Sunesis Pharmaceuticals stock can currently be purchased for approximately $1.85.

MarketBeat Community Rating for Sunesis Pharmaceuticals (NASDAQ SNSS)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  150 (Vote Outperform)
Underperform Votes:  148 (Vote Underperform)
Total Votes:  298
MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sunesis Pharmaceuticals (NASDAQ:SNSS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $3.00 (62.16% upside)
Consensus Price Target History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Price Target History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Analysts' Ratings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/27/2017Cantor FitzgeraldReiterated RatingHold$3.00LowView Rating Details
11/3/2016Cowen and CompanyReiterated RatingHoldN/AView Rating Details
7/29/2016Wells Fargo & CompanyUpgradeMarket Perform -> OutperformN/AView Rating Details
(Data available from 10/24/2015 forward)


Earnings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Earnings by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Earnings History by Quarter for Sunesis Pharmaceuticals (NASDAQ SNSS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.41)N/AView Earnings Details
7/27/2017Q2 2017($0.76)($0.41)$2.40 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.83)($0.47)$1.57 million$0.67 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.43)($0.44)$0.60 million$0.68 millionViewListenView Earnings Details
11/3/2016Q316($0.71)($0.62)$0.60 million$0.60 millionViewN/AView Earnings Details
7/29/2016Q216($0.10)($0.12)$0.70 million$0.60 millionViewListenView Earnings Details
5/5/2016Q116($0.12)($0.12)$0.77 million$0.64 millionViewListenView Earnings Details
3/10/2016Q415($0.14)($0.15)$0.84 million$0.67 millionViewListenView Earnings Details
11/5/2015Q315($0.12)($0.09)$1.09 million$0.68 millionViewListenView Earnings Details
7/30/2015Q215($0.13)($0.15)$1.21 million$0.85 millionViewN/AView Earnings Details
5/5/2015Q115($0.16)($0.13)$1.14 million$0.90 millionViewListenView Earnings Details
3/12/2015Q414($0.20)($0.02)$1.17 million$0.90 millionViewListenView Earnings Details
11/10/2014Q314($0.17)($0.25)$1.97 million$0.85 millionViewListenView Earnings Details
8/5/2014Q214($0.17)($0.20)$1.32 million$2.00 millionViewListenView Earnings Details
5/7/2014Q114($0.17)($0.26)$1.32 million$2.00 millionViewListenView Earnings Details
3/6/2014Q413($0.20)($0.15)$1.37 million$2.00 millionViewListenView Earnings Details
11/12/2013Q313($0.20)($0.16)$1.44 million$1.99 millionViewListenView Earnings Details
7/29/2013Q2 2013($0.21)$0.18$1.22 million$1.99 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.20)($0.23)$0.75 million$1.99 millionViewListenView Earnings Details
3/13/2013Q4 2012($0.19)($0.20)$0.32 million$1.99 millionViewListenView Earnings Details
11/8/2012Q312($0.11)($0.37)$4.17 million$0.26 millionViewN/AView Earnings Details
8/9/2012($0.20)($0.20)ViewN/AView Earnings Details
5/15/2012($0.18)($0.30)ViewN/AView Earnings Details
11/14/2011($0.18)($0.11)ViewN/AView Earnings Details
8/11/2011($0.15)($0.18)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Current Year EPS Consensus Estimate: $-1.61 EPS
Next Year EPS Consensus Estimate: $-1.39 EPS


Dividend History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Insider Ownership Percentage: 10.21%
Institutional Ownership Percentage: 57.54%
Insider Trades by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Institutional Ownership by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Insider Trades by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/9/2016Geoffrey M ParkerDirectorBuy3,740$3.87$14,473.80View SEC Filing  
5/26/2016Geoffrey M ParkerDirectorBuy9,500$0.47$4,465.00View SEC Filing  
5/25/2016Geoffrey M ParkerDirectorBuy52,505$0.47$24,677.35View SEC Filing  
12/21/2015Dayton MisfeldtDirectorBuy1,750,000$0.84$1,470,000.00View SEC Filing  
8/25/2015Daniel N Swisher JrCEOBuy12,216$1.01$12,338.16View SEC Filing  
8/24/2015Daniel N Swisher JrCEOBuy12,784$1.01$12,911.84View SEC Filing  
8/29/2014Forest BaskettMajor ShareholderSell266,700$7.97$2,125,599.00View SEC Filing  
8/28/2014Bay City Capital LlcMajor ShareholderSell300,700$7.98$2,399,586.00View SEC Filing  
8/28/2014Dayton MisfeldtDirectorSell200,000$7.89$1,578,000.00View SEC Filing  
8/27/2014Adam R CraigCMOSell2,554$8.00$20,432.00View SEC Filing  
8/27/2014Daniel N Swisher JrCEOSell5,000$8.00$40,000.00View SEC Filing  
8/27/2014Dayton MisfeldtDirectorSell100,700$8.16$821,712.00View SEC Filing  
8/27/2014Eric BjerkholtCFOSell10,000$8.00$80,000.00View SEC Filing  
8/27/2014Krishna Kittu KolluriMajor ShareholderSell108,300$8.17$884,811.00View SEC Filing  
8/12/2014Dayton MisfeldtDirectorSell743,700$6.64$4,938,168.00View SEC Filing  
8/12/2014Equity Opportunities Fu GrowthMajor ShareholderSell710,540$6.63$4,710,880.20View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Latest Headlines for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Loading headlines, please wait.



Sunesis Pharmaceuticals (SNSS) Chart for Tuesday, October, 24, 2017

This page was last updated on 10/24/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.